p 26

SARS-CoV-2 Spike S1 Protein (L18F & T20N & P26S & D138Y & R190S & K417T & E484K & N501Y & D614G & H655Y, His & Avi), Biotinylated is expressed in HEK293 mammalian cells with His and Avi tag. The predicted molecular weight is 78.28 kDa and the accession number is A0A6G7K2L4.

SARS-CoV-2 Spike S1+S2 Protein (L18F & T20N & P26S & D138Y & R190S & K417T & E484K & N501Y & D614G & H655Y & T1027I, His) is expressed in Baculovirus insect cells with His tag. The predicted molecular weight is 134.4 kDa and the accession number is A0A6G7K2L4.

SARS-CoV-2 Spike S1+S2 Protein (L18F & T20N & P26S & D138Y & R190S & K417T & E484K & N501Y & D614G & H655Y & T1027I & V1176F, His) is expressed in Baculovirus insect cells with His tag. The predicted molecular weight is 134.5 kDa and the accession number is A0A6G7K2L4.

May act as transcriptional regulator. Induces apoptosis in infected cells. Element of infectious replication cycle. Chicken anemia virus (isolate USA 26p4) Apoptin Protein (His) is expressed in E. coli expression system with N-6xHis tag. The predicted molecular weight is 17.1 kDa and the accession number is P54095.

SARS-CoV-2 Spike S1 Protein (P26S & 69-70 deletion & V126A & Y144 deletion & 241-243 deletion & H245Y & S477N & E484K & D614G & P681H, His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 75.77 kDa and the accession number is A0A6G7K2L4.

SARS-CoV-2 Spike S1+S2 Protein (P26S, 69-70 deletion & V126A & Y144 deletion & 241-243 deletion & H245Y & S477N & E484K & D614G & P681H & T1027I & D1118H, His) is expressed in Baculovirus insect cells with His tag. The predicted molecular weight is 133.72 kDa and the accession number is A0A6G7K2L4.

SARS-CoV-2 Spike S1 Protein (L18F & T20N & P26S & D138Y & R190S & K417T & E484K & N501Y & D614G & H655Y, His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 76.5 kDa and the accession number is A0A6G7K2L4.

CLEC2C (CD69) is a membrane-bound, type II C-lectin receptor and acts as a costimulatory molecule for T cell activation and proliferation. It is involved in lymphocyte proliferation and functions as a signal transmitting receptor in lymphocytes, natural killer (NK) cells, and platelets. CLEC2C is a disulfide-linked homodimer protein with two differentially glycosylated subunits.

p53, also known as Tp53, is a DNA-binding protein which belongs to the p53 family. It contains transcription activation, DNA-binding, and oligomerization domains. p53 protein is expressed at low level in normal cells and at a high level in a variety of transformed cell lines, where it's believed to contribute to transformation and malignancy. p53 (TP53) is a transcription factor whose protein levels and post-translational modification state alter in response to cellular stress (such as DNA damage, hypoxia, spindle damage). Activation of p53 begins through a number of mechanisms including phosphorylation by ATM, ATR, Chk1 and MAPKs. MDM2 is a ubiquitin ligase that binds p53 and targets p53 for proteasomal degradation. Phosphorylation, p14ARF and USP7 prevent MDM2-p53 interactions, leading to an increase in stable p53 tetramers in the cytoplasm. Further modifications such as methylation and acetylation lead to an increase in Tp53 binding to gene specific response elements. Tp53 regulates a large number of genes (>100 genes) that control a number of key tumor suppressing functions such as cell cycle arrest, DNA repair, senescence and apoptosis. Whilst the activation of p53 often leads to apoptosis, p53 inactivation facilitates tumor progression. It is postulated to bind to a p53-binding site and activate expression of downstream genes that inhibit growth and/or invasion, and thus function as a tumor suppressor. Mutants of p53 that frequently occur in a number of different human cancers fail to bind the consensus DNA binding site, and hence cause the loss of tumor suppressor activity. Defects in TP53 are a cause of esophageal cancer, Li-Fraumeni syndrome, lung cancer and adrenocortical carcinoma.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy